BD's Q2 Revenues Drop Slightly While Biosciences Biz Rises 3 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its second-quarter revenues were down less than 1 percent year over year, but its BD Biosciences segment managed three percent revenue growth for the quarter.

The Franklin Lakes, NJ-based maker of diagnostics, medical products, and life science research tools reported revenues of $1.74 billion for the three-month period ended March 31, down from revenues of $1.75 billion in the second quarter of 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.